ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic Oct 27 • 4 min read ATAI Life Sciences announced that Neuronasal Inc. has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers.
Field Trip Health Ltd. : Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago Oct 26 • 7 min read Field Trip Health Ltd. announced the opening of their Chicago center.
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms Oct 22 • 7 min read Numinus Wellness Inc. has harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence.
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson’s Disease Oct 21 • 6 min read Pharmather Inc. announced it has filed an application with the U.S. FDA to receive Orphan Drug Designation for ketamine.
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds Oct 20 • 6 min read Revive Therapeutics Ltd. announced it has signed an agreement with Havn Life Sciences Inc. to source naturally-derived psychedelic compounds for use in future investigational new drug.